OMEICOS Therapeutics GmbH - News

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk

Berlin, Germany, July,17 2018 – OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced results from its first-in-human clinical study for OMT-28.

Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics

Appointment marks further progress in ramping-up US-based subsidiary as validation of OMEICOS’ lead compound also progresses through clinical trials in atrial fibrillation

Berlin, Germany, and Boston, MA, USA, April 27, 2018 – OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of Alexander Gebauer, MD, Ph.D., to the Company’s Management Board.

OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Leading Experts in Atrial Fibrillation to Complement the Company’s Key Focus Area

Berlin, Germany, November 13, 2017 — OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of leading experts in the field of cardiac arrhythmias to the company’s Clinical Advisory Board (CAB). The multinational group of specialists will serve as a strategic resource to OMEICOS as it continues to advance its lead compound, OMT-28, currently in a Phase I clinical trial. The CAB will provide counsel to the company as OMEICOS starts to design a Phase II program for maintenance of sinus rhythm in patients with atrial fibrillation.

OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology

OMEICOS adds REMIGES Ventures as new investor and announces the incorporation of U.S. subsidiary OMEICOS Ophthalmics, Inc.

Berlin, Germany, and Boston, MA, USA, October 04, 2017 — OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing by US-based REMIGES Ventures will help to expand the development of OMEICOS’ technology into the field of ophthalmological disorders. The company’s novel technology is based on stable synthetic small molecules which mimic natural highly bioactive lipid mediators derived from omega-3 fatty acids. REMIGES Ventures joins the existing investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF) and KfW Group. Financial details of the additional investment were not disclosed.

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Indication Areas

Berlin, Germany, June 07, 2017 — OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of a new grant by the German Ministry of Education and Research (BMBF). The grant of approximately €1.7 million covers half of the investment needed to advance an OMEICOS research project with the other half coming from the funds secured in a Series B round from an investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF), KfW Group and The Falck Revocable Trust, Ascenion GmbH and members of the management team earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat cardiovascular diseases and to explore its potential in other areas of high unmet medical need. With this renewed support from the German government as part of the Ascenion Spinnovator program, OMEICOS has secured so far roughly €4 million non-dilutive funding.